The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress.
 
Els Van Nieuwenhuysen
Consulting or Advisory Role - AstraZeneca (Inst); Merck Serono (Inst); Oncoinvent; Regeneron (Inst)
Speakers' Bureau - AstraZeneca (Inst); GlaxoSmithKline (Inst); MSD
Research Funding - AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncoinvent (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline (Inst); Regeneron (Inst)
 
Judith Michels
Consulting or Advisory Role - Abbvie; GlaxoSmithKline; Regeneron Pharmaceuticals, Inc.;; Replimune
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Merck; Merck
 
Hee Seung Kim
No Relationships to Disclose
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Abbvie; AstraZeneca; BeOne; BioNTech; Corcept Therapeutics; Eisai; Genmab; Gilead Sciences; GlaxoSmithKline; Immunogen; Incyte; Lilly; MSD Oncology; Novocure; Regeneron; Seagen
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novocure; Nuvation Bio; OCXERNA; Pieris Pharmaceuticals; Roche/Genentech
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; MSD Oncology
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Corcept Therapeutics; GlaxoSmithKline
 
P. Ottevanger
Consulting or Advisory Role - GlaxoSmithKline (Inst)
 
Roisin O'Cearbhaill
Honoraria - Aptitude Health; Cardinal Health; Curio Science; GlaxoSmithKline; GOG Foundation; MJH/PER
Consulting or Advisory Role - GlaxoSmithKline; GOG Foundation; Immunogen; Loxo/Lilly; Regeneron; Seagan; Takeda Science Foundation
Research Funding - Acrivon Therapeutics (Inst); ArsenalBio (Inst); AstraZeneca/Merck (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Iovance Biotherapeutics (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Ludwig Institute for Cancer Research (Inst); Lyell Immunopharma (Inst); Merck/Genentech (Inst); Mural Oncology (Inst); OnCusp Therapeutics (Inst); Regeneron (Inst); Sellas Life Sciences (Inst); Syndax (Inst); TapImmune Inc. (Inst); TCR2 Therapeutics (Inst)
Travel, Accommodations, Expenses - Gathering Around Cancer; Society of Gynecologic Oncology
Other Relationship - JAMA Oncology
 
Ruth Perets
No Relationships to Disclose
 
An Reyners
No Relationships to Disclose
 
Suk-Young Yoo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Bin Wang
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Jurriaan Brouwer
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Mihaela Cristea
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Nicole Costigan
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Mary Peterman
Employment - Regeneron
Stock and Other Ownership Interests - Merck; Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Brigid Barnes
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Elizabeth Miller
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - involved in patents through employment at Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Gloria Huang
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - United States Patent 17102992, Issued October 31, 2023. Inventor. (Inst)
 
Thomas Uldrick
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - As an employee of Fred Hutchinson Cancer Center, I am named on a US Provisional Application No 63/337,8814, KSHV Oncoprotein antigens and epitopes for expanding KSHV-antigen specific T cells. (Inst); As an employee of Regeneron Pharmaceuticals, I am named on a US Patent 20230312718, "Methods for treating recurrent ovarian cancer with bispecific MUC16xCD3 antibodies alone or in combination with anti-PD1 antibodies" (Inst); As an employee of Regeneron Pharmaceuticals, I am named on a US Patent Application 63/608,922, "Methods of Treating Endometrial Cancer with Bispecific anti-MUC16 anti-CD3 antibodies alone and in combination with anti-PD1 antibodies" (Inst); As an employee of the U.S. Government, I have provisional patent application regarding methods for the treatment of Kaposi’s sarcoma and KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (Inst)
(OPTIONAL) Uncompensated Relationships - Fred Hutchinson Cancer Research Center